The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The experience of single-agent daratumumab for R/R myeloma in India
Lalit Kumar, MD, MBBS, All India Institute of Medical Sciences, New Delhi, India, discusses a Phase IV study of daratumumab for relapsed/refractory (R/R) multiple myeloma (MM) in India. Over 140 patients were included in the analysis, including those who were R/R following treatment with bortezomib or lenalidomide, and a response rate of nearly 30% was achieved. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
